SUMMARY, EXPLANATION AND LIMITATIONS:
The Bcl-6 proto-oncogene encodes for a zinc finger protein of about 92 – 98 kDa. This protein binds to nuclear DNA and acts as a transcriptional repressor. The expression of Bcl-6 protein in general is ubiquitous and, therefore, small amounts of this protein are detectable in a lot of cell types. However, strong Bcl-6 expression is only found in B-cells and skeletal muscles. In B-cells of germinal centres high expression levels are detectable but not in precursor cells, mantle zone cells, and plasma cells. Germ centre B-cell derived neoplasms like Burkitt´s lymphoma, follicular lymphoma, and diffuse large cell lymphoma are showing high expression levels too. The analysis of Bcl-6 expression is useful to distinguish proliferating centres in B-cells (bcl6-/bcl2+) from trapped germinal centres with mantle cell lymphoma (bcl6+/bcl2-). The identification of neoplasmic cells in cases of nodular Hodkin´s lymphoma which is characterised by a predominance of lymphocytes is also possible.
Immunogen: Recombinant protein pcDNA3-bcl-6 of human Bcl-6.
Staining pattern: Nuclear.
Positive control: Tissue sample from lymph node or tonsil.
This antibody is designed for the specific localization of human Bcl-6 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
Bcl-6 has been detected by immunohistochemistry in germinal center B-cell lymphoma (follicular lymphoma), diffuse large B-cell lymphomas, Burkitt lymphomas and in classical Hodgkin’s disease and nodular sclerosis variant of lymphocytic predominance. Bcl-6 is not expressed in B-chronic lymphocytic leukemia, hairy cell leukemia, mantle derived lymphomas or marginal area.